Data altruism and the "consent" question: a study into the "consent" models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Frontiers in Medicine Pub Date : 2025-02-25 eCollection Date: 2024-01-01 DOI:10.3389/fmed.2024.1489925
Maria Christofidou, Theodoros N Arvanitis, Dipak Kalra, Nathan Lea, Mahsa Shabani, Pascal Coorevits
{"title":"Data altruism and the \"consent\" question: a study into the \"consent\" models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data.","authors":"Maria Christofidou, Theodoros N Arvanitis, Dipak Kalra, Nathan Lea, Mahsa Shabani, Pascal Coorevits","doi":"10.3389/fmed.2024.1489925","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The General Data Protection Regulation (\"GDPR\") legal basis for obtaining consent for the processing of personal data for research purposes, where those purposes cannot be fully specified in advance, is provided for in Articles 6, 7 and Recital 33. However, GDPR's requirements for obtaining consent, as to the secondary use and sharing of data in research, have been argued to have generated confusion, whilst the conflicts between the Regulation itself, its practical application and research ethics are well-documented (1). The requirements for \"informed consent\", as defined within the GDPR, have not been well defined in the context of genome research or clinical trials (2), which has in turn led to the implementation and interpretation of the lawful basis to span into different idiosyncratic models. This naturally has fed into the uncertainty of how the legal basis can be applied in practice and calls for an investigation into the requirements for consent to be \"informed\" in the context of health research. This work aims to provide a scoping review and analysis of relevant publications with ultimate purpose to examine whether the concept of 'data altruism', as stipulated within Article 2 (10) of the Data Governance Act (\"DGA\"), addresses the gaps left behind by the application of the legal basis of 'consent', under the GDPR (Art. 6 (1) and 7), in so far as the secondary uses of data for research are concerned. In this light the article, by exploring available solutions found in relevant literature and used in practice in national and European projects, examines how 'data altruism' can add any value and work as a cohesive solution that the research community can use.</p><p><strong>Objectives: </strong>The article, through its research, intends to answer the following questions:What gaps has the GDPR left when it comes to the interpretation and practical application of \"consent\" towards the secondary use of health data;Can the DGA, through the mechanism of 'data altruism', address these issues and provide a solution;What solutions have been used so far in practice to address this issue.</p><p><strong>Methodology: </strong>To address the above-mentioned questions, the Arskey and O'Malley scoping review methodology and best practice, as outlined in the Joanna Briggs scoping review guidelines, have been applied. The research questions have been identified through an extensive literature review and consultation with subject matter experts. The search was conducted using six search engines and utilising a tailored search strategy, with the application of both MESH and non-MESH based search terms. From the identified relevant publications, 148 abstracts were kept to be read and 60 of those publications were kept as relevant. A PRISMA chart showcases the process in which the publications were reviewed and the process which led to the final papers kept as relevant. The title-abstract and full text screening and charting the data were concluded independently by two reviewers. Discrepancies were then resolved by a third reviewer. Results are summarised in both chart and narrative form below.</p><p><strong>Results: </strong>The final 60 publications were then split into three subcategories: (i) GDPR critique (23 publications listed); (ii) iterations of consent and data altruism (21 publications listed); and (iii) proposed solutions and current practices (31 publications). Certain of the publications fell into more than one of the above subcategories, given the interdisciplinary element of the subject and theme of each paper. Throughout the research, 5 of the publications discuss the Data Governance Act and data altruism, with 4 of those providing a critique over the text used in the DGA and the concept of 'data altruism' in relation to 'consent' as defined within the GDPR and the overall legislative framework for the secondary uses of data.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"11 ","pages":"1489925"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894576/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1489925","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The General Data Protection Regulation ("GDPR") legal basis for obtaining consent for the processing of personal data for research purposes, where those purposes cannot be fully specified in advance, is provided for in Articles 6, 7 and Recital 33. However, GDPR's requirements for obtaining consent, as to the secondary use and sharing of data in research, have been argued to have generated confusion, whilst the conflicts between the Regulation itself, its practical application and research ethics are well-documented (1). The requirements for "informed consent", as defined within the GDPR, have not been well defined in the context of genome research or clinical trials (2), which has in turn led to the implementation and interpretation of the lawful basis to span into different idiosyncratic models. This naturally has fed into the uncertainty of how the legal basis can be applied in practice and calls for an investigation into the requirements for consent to be "informed" in the context of health research. This work aims to provide a scoping review and analysis of relevant publications with ultimate purpose to examine whether the concept of 'data altruism', as stipulated within Article 2 (10) of the Data Governance Act ("DGA"), addresses the gaps left behind by the application of the legal basis of 'consent', under the GDPR (Art. 6 (1) and 7), in so far as the secondary uses of data for research are concerned. In this light the article, by exploring available solutions found in relevant literature and used in practice in national and European projects, examines how 'data altruism' can add any value and work as a cohesive solution that the research community can use.

Objectives: The article, through its research, intends to answer the following questions:What gaps has the GDPR left when it comes to the interpretation and practical application of "consent" towards the secondary use of health data;Can the DGA, through the mechanism of 'data altruism', address these issues and provide a solution;What solutions have been used so far in practice to address this issue.

Methodology: To address the above-mentioned questions, the Arskey and O'Malley scoping review methodology and best practice, as outlined in the Joanna Briggs scoping review guidelines, have been applied. The research questions have been identified through an extensive literature review and consultation with subject matter experts. The search was conducted using six search engines and utilising a tailored search strategy, with the application of both MESH and non-MESH based search terms. From the identified relevant publications, 148 abstracts were kept to be read and 60 of those publications were kept as relevant. A PRISMA chart showcases the process in which the publications were reviewed and the process which led to the final papers kept as relevant. The title-abstract and full text screening and charting the data were concluded independently by two reviewers. Discrepancies were then resolved by a third reviewer. Results are summarised in both chart and narrative form below.

Results: The final 60 publications were then split into three subcategories: (i) GDPR critique (23 publications listed); (ii) iterations of consent and data altruism (21 publications listed); and (iii) proposed solutions and current practices (31 publications). Certain of the publications fell into more than one of the above subcategories, given the interdisciplinary element of the subject and theme of each paper. Throughout the research, 5 of the publications discuss the Data Governance Act and data altruism, with 4 of those providing a critique over the text used in the DGA and the concept of 'data altruism' in relation to 'consent' as defined within the GDPR and the overall legislative framework for the secondary uses of data.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
数据利他主义和“同意”问题:对GDPR下使用的“同意”模型的研究,以及数据利他主义机制如何作为研究界在重用健康数据方面的潜在解决方案。
导言:通用数据保护条例(“GDPR”)为研究目的而获得个人数据处理同意的法律依据,如果这些目的不能事先完全指定,则在第6条,第7条和序言33条中提供。然而,关于在研究中数据的二次使用和共享,GDPR对获得同意的要求被认为产生了混乱,而法规本身、其实际应用和研究伦理之间的冲突是有据可据的(1)。GDPR中定义的“知情同意”的要求在基因组研究或临床试验的背景下没有得到很好的定义(2)。这反过来又导致了对法律基础的实施和解释跨越了不同的特殊模式。这自然造成了如何在实践中适用法律基础的不确定性,并要求调查在健康研究方面“知情”同意的要求。这项工作旨在对相关出版物进行范围审查和分析,最终目的是检查“数据治理法案”(“DGA”)第2(10)条规定的“数据利他主义”概念是否解决了GDPR(第6(1)条和第7条)下“同意”法律基础的应用所留下的差距,就研究数据的二次使用而言。在这种情况下,本文通过探索相关文献中发现的可用解决方案,并在国家和欧洲项目的实践中使用,研究了“数据利他主义”如何增加任何价值,并作为研究界可以使用的有凝聚力的解决方案发挥作用。目的:本文旨在通过研究回答以下问题:GDPR在对健康数据二次使用的“同意”的解释和实际应用方面留下了哪些差距;DGA能否通过“数据利他主义”的机制解决这些问题并提供解决方案;迄今为止在实践中使用了哪些解决方案来解决这一问题。方法论:为了解决上述问题,Arskey和O'Malley的范围审查方法和最佳实践,如Joanna Briggs范围审查指南中概述的,已经被应用。通过广泛的文献回顾和咨询主题专家,确定了研究问题。是次搜索使用了六个搜索引擎,并采用了量身定制的搜索策略,使用了基于MESH和非MESH的搜索词。从已查明的有关出版物中,保留148份摘要供阅读,其中60份作为有关出版物保留。PRISMA图表显示了审查出版物的过程以及导致最终文件保持相关的过程。标题摘要和全文筛选及数据图表由两位审稿人独立完成。然后由第三位审稿人解决差异。结果以图表和叙述形式总结如下。结果:最后的60份出版物被分成三个子类别:(i) GDPR评论(列出的23份出版物);(ii)同意和数据利他主义的迭代(列出的21份出版物);(三)提出的解决方案和目前的做法(31篇出版物)。鉴于每篇论文的学科和主题的跨学科因素,某些出版物属于以上一个以上的子类别。在整个研究过程中,有5份出版物讨论了《数据治理法案》和数据利他主义,其中4份对DGA中使用的文本以及与GDPR中定义的“同意”相关的“数据利他主义”概念以及数据二次使用的整体立法框架提出了批评。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
期刊最新文献
Case Report: Congenital gallbladder agenesis. Barriers affecting medication adherence to dienogest among patients with ovarian endometriosis: a qualitative study. Distribution of static and dynamic cyclotorsion and influencing factors in FS-LASIK. Analysis of risk factors for anastomotic fistula in patients after laparoscopic radical resection for rectal cancer. An unusual trilogy: a case of comorbid aHUS, Fabry disease, and hypertrophic cardiomyopathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1